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Purpose: Spontaneous bacterial peritonitis (SBP) frequently develops in patients 
with liver cirrhosis; however, there is little data to suggest whether the acquisition 
site of infection influences the prognosis. This study compared the bacteriology, 
clinical characteristics and treatment outcomes of community-acquired SBP (CA-
SBP) and nosocomial SBP (N-SBP). Materials and Methods: The medical re-
cords of 130 patients with hepatitis B virus (HBV)-related liver cirrhosis, who had 
experienced a first episode of SBP between January 1999 and December 2008, 
were reviewed. Results: The study population included 111 (85.4%) patients with 
CA-SBP and 19 (14.6%) patients with N-SBP. Baseline and microbiological char-
acteristics as well as clinical course, including in-hospital mortality, did not differ 
between patients with CA-SBP and those with N-SBP (all p>0.05). The median 
survival time was 6.5 months, and 117 (90.0%) patients died during the follow-up 
period. Patients with CA-SBP and N-SBP survived for median periods of 6.6 and 
6.2 months, respectively, without significant difference (p=0.569). Time to recur-
rence did not differ between patients with CA-SBP and N-SBP (4.7 vs. 3.6 months, 
p=0.925). Conclusion: The acquisition site of infection did not affect clinical out-
comes for patients with HBV-related liver cirrhosis who had experienced their first 
episode of SBP. Third-generation cephalosporins may be effective in empirically 
treating these patients, regardless of the acquisition site of the infection.
Key Words:   Ascites, cirrhosis, community-acquired, nosocomial, spontaneous 
bacterial peritonitis
INTRODUCTION
Spontaneous bacterial peritonitis (SBP) is an ascitic fluid infection without a defin-
itive, surgically treatable, intra-abdominal source and is a drastic complication of 
end-stage liver disease, occurring in 10 to 25% of cirrhotic patients with ascites.1,2 
Although mortality related to SBP has markedly decreased over the last 3 decades, 
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went a liver transplantation during the follow-up period 
were also excluded to remove confounding effects of these 
factors on survival. In addition, patients whose ascites were 
caused by tuberculosis or malignancy or whose culture re-
sults suggested secondary bacterial peritonitis (polymicrobi-
al infection) or contamination by skin or medical appliances 
(coagulase-negative staphylococci, corynebacterium, propi-
onibacterium, or bacillus species) were excluded. The proto-
col of this study was consistent with the ethical guidelines of 
the 1975 Declaration of Helsinki and was approved by the 
independent institutional review boards of each institute. 
Definitions of variables
The diagnostic criteria for SBP were a positive ascitic fluid 
culture with an elevated (>250 cells/mm3) ascitic polymor-
phonuclear leukocyte (PMN) count and/or a positive ascitic 
fluid culture.14-16 SBP diagnosis within the first 48 hours of 
hospitalization was categorized as CA-SBP, while diagno-
sis more than 48 hours after hospitalization was defined as 
N-SBP.13,17
Variceal bleeding, hepatic encephalopathy (HE), renal 
failure, blood culture positivity, antibiotic switching during 
hospitalization and in-hospital mortality were reviewed to 
compare the clinical courses of patients with CA-SBP and 
N-SBP. An esophago-gastro-duodenoscopy was required to 
confirm variceal bleeding. HE was defined as an episode of 
asterixis, mental confusion, loss of orientation, excitation or 
abnormal behavior.18 Renal failure was defined as >50% in-
crease (vs. pretreatment value) of blood urea nitrogen or se-
rum creatinine level of more than 30 mg/dL or 1.5 mg/dL, 
respectively, in patients with normal renal function at the 
time of enrollment. For patients with preexisting renal im-
pairment, a diagnosis of renal failure required an increase in 
blood urea nitrogen or serum creatinine level greater than 
50% from baseline.19
Paracentesis and laboratory techniques
Bacterial identification and antibiotic susceptibility tests 
were performed according to standard procedures estab-
lished by the Clinical and Laboratory Standards Institute, 
following our previously described methods.20 
Paracentesis was carried out using a 23-gauge sterile nee-
dle under local anesthesia with lidocaine. After withdrawal 
from the abdomen, this skin needle was replaced with a ster-
ile needle to minimize contamination by skin flora. Within 3 
hours of aspiration, the obtained peritoneal fluids were sent 
to the laboratory to calculate the PMN counts and to perform 
due to earlier recognition of the infection followed by ad-
ministration of effective antibiotics, it continues to be high, 
ranging from 20 to 40%.3-5 In addition, the one-year surviv-
al rate after recovery from the first episode of SBP is only 
30 to 40%.6
Intestinal bacterial overgrowth and subsequent transloca-
tion of bacteria from the intestines to the mesenteric lymph 
nodes is known to be a critical step in the pathogenesis of 
SBP.7,8 In patients with liver cirrhosis, impairment of the im-
mune system, due to complement deficiencies and neutro-
philic malfunction, hampers clearing bacteria from the asci-
tes, facilitating the development of SBP.9,10 Thus, patients 
with liver cirrhosis are susceptible to bacterial infections 
both inside and outside the hospital.
To date, few studies have investigated the effects of the 
acquisition site of infection (community-acquired vs. noso-
comial) on clinical outcomes in patients with liver cirrhosis 
with accompanying SBP.11-13 However, factors such as vari-
ous etiologies of liver cirrhosis, history of previous SBP,11,13 
and hepatocellular carcinoma (HCC) at the time of SBP di-
agnosis might have confounded exact comparisons be-
tween patients with community-acquired SBP (CA-SBP) 
and nosocomial SBP (N-SBP) in previous studies.11-13  Fur-
thermore, differences in baseline liver function at the time 
of CA-SBP or N-SBP diagnosis11 might have disturbed ex-
act comparisons of their prognoses.
Therefore, this study focused on patients with hepatitis B 
virus (HBV)-related liver cirrhosis who had experienced 
their first episode of SBP. We compared microbiological 
and clinical characteristics as well as treatment outcomes 
(in-hospital clinical course, time to recurrence, and overall 
survival) of patients with CA-SBP and N-SBP. 
MATERIALS AND METHODS
　　　
Patients 
The medical records of 130 patients with HBV-related liver 
cirrhosis who had experienced their first episode of SBP 
and were treated at either Severance Hospital (College of 
Medicine, Yonsei University, Seoul, Korea) or at the Na-
tional Health Insurance Corporation Ilsan Hospital (Goy-
ang, Korea) between January 1999 and December 2008, 
were reviewed. Patients with a history of previous SBP or 
non-HBV etiologies of cirrhosis, such as hepatitis C virus 
or alcohol abuse, were excluded. Patients with coexisting 
HCC at the time of SBP diagnosis and those who under-
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analysis was used to identify independent predictors for in-
hospital mortality. Independent prognostic factors for over-
all survival were identified with a proportional hazards Cox 
regression model, and corresponding hazard ratios (HR) 
and 95% confidence intervals (CI) were calculated. The cu-
mulative probability of death or disease recurrence was an-
alyzed by the Kaplan-Meier method. Time to recurrence 
and overall survival were compared between patients with 
CA-SBP and N-SBP using the log rank test. All statistical 
analyses were performed using the SPSS software package 
(Version 12.0, SPSS Inc., Chicago, IL, USA), and two-sid-
ed p-values <0.05 were considered statistically significant.
RESULTS
 
Baseline characteristics
Table 1 shows the baseline characteristics of the study pop-
ulation at the time of diagnosis. A total of 130 patients (88 
male and 42 female) had a mean age of 53.3 years (range, 
44.9-61.7 years). One hundred and eleven (85.4%) patients 
had CA-SBP, whereas 19 (14.6%) had N-SBP. Patients 
with N-SBP were initially admitted for the management of 
jaundice (n=7), gastrointestinal bleeding (n=6), poor oral 
intake (n=3), and HE (n=3). Among six patients with N-
SBP who were admitted due to gastrointestinal bleeding, 
two were given ciprofloxacin on admission as a prophylac-
tic. However, the antibiotic agent was changed to cefotaxi-
me after they were diagnosed with N-SBP. No significant 
differences were found between patients with CA-SBP and 
N-SBP in regards to age, gender, history of previous varice-
al bleeding or HE, and Child-Pugh scores (all p>0.05). Al-
though the results of the serological and ascitic fluid tests 
were comparable, the average serum white blood cell count 
was significantly higher in patients with CA-SBP than those 
with N-SBP (8197±4978 vs. 4780±2244/mm3, p=0.006), 
while the mean serum sodium level was significantly high-
er in patients with N-SBP than those with CA-SBP (135.4± 
5.8 vs. 131.6±5.8 mmol/L, p=0.007).
Paracentesis 
All 111 patients with CA-SBP underwent their first para-
centesis within 24 hours of hospital admission [median, 2 h 
(range, 1-20)] and were diagnosed with SBP. By contrast, 
all 19 N-SBP patients with accompanying ascites showed 
negative results for SBP on the initial admission paracente-
sis [median, 2 h (range, 1-24)]. However, due to fever (n=8), 
gram staining. Ascitic fluid samples (10 mL) were then inoc-
ulated into aerobic and anaerobic blood bottles (bioMerieux, 
Durham, NC, USA) and cultured with an automated BacT/
Alert 3D culture system (bioMerieux, Durham, NC, USA). 
Conventional culture methods (i.e., inoculating blood agar, 
MacConkey agar, and phenylethanol agar and thioglycollate 
broth) were used on the remaining fluid from each sample. 
The conventional agar and broth media were incubated at 
35°C for up to 3 days before being discarded as negative. 
Diagnosis and treatment algorithm
According to the guidelines of our institute, all patients with 
ascites upon admission routinely underwent paracentesis 
within 24 h of admission.21 If the symptoms and laboratory 
results were indicative of SBP, 2 g cefotaxime every 8 hours 
was administered as the initial antibiotic treatment for all 
patients and was continued until recovery, antibiotic switch-
ing, or death. Follow-up paracentesis was scheduled 48 
hours after antibiotic administration to evaluate treatment 
response or when clinical or laboratory findings did not 
show typical improvement. Treatment failure was defined 
as a decrease of less than 50% in ascitic fluid PMN count, 
in cases where follow-up paracentesis was performed.21 An-
tibiotics were switched according to the culture and sensi-
tivity results of the initial ascitic fluid test, treatment failure, 
or persistent clinical deterioration. Intravenous albumin was 
infused using the recommended protocol.19 Recovery from 
SBP was clinically assessed by the disappearance of symp-
toms or by negative cultures and reduction in ascitic fluid 
PMN count to less than 250/mm3.22 Norfloxacin was ad-
ministered after recovery for prophylaxis.23
Survival and recurrence calculation
Survival time was calculated from the date of the first SBP 
diagnosis to death. In-hospital mortality was assessed by 
counting deaths during hospitalization, and overall mortali-
ty was evaluated by counting the number of deaths that oc-
curred throughout the entire follow-up period (to December 
2009). Time to recurrence was defined as the period between 
discharge from the hospital after the first SBP episode to 
the next SBP episode.
Statistical analysis
All variables are reported as mean±standard deviation, me-
dian (range), or number (%). Independent t-tests were used 
to compare continuous variables, and chi-square tests were 
used for categorical variables. Binary logistic regression 
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ic fluid samples [32 (28.8%) with CA-SBP vs. 5 (26.3%) with 
N-SBP]. The most common organism in patients with CA-
SBP and N-SBP was Escherichia coli [20 (62.5%) with CA-
SBP vs. 3 (60.0%) with N-SBP]. No significant differences 
in microorganisms were identified between the two groups 
(p=0.961). 
Clinical course during hospitalization
Table 3 shows the clinical courses of patients with CA-SBP 
and N-SBP during hospitalization. The incidence of liver-re-
lated complications such as variceal bleeding, HE, and renal 
failure did not differ between the two groups (all p>0.05). 
Furthermore, blood culture positivity (p=0.578), antibiotic 
switching (p=0.066), and in-hospital mortality (p=0.163) 
did not differ. 
abdominal distension (n=7), and abdominal pain (n=4), N-
SBP patients received a second paracentesis procedure. Af-
ter 8.2 days (range, 3.8-12.2) of hospital admission, all 19 
patients were diagnosed with N-SBP.
A scheduled follow-up paracentesis at 48 hours after the 
initial antibiotic administration was performed in 76 pa-
tients [67 (60.4%) with CA-SBP vs. 9 (47.4%) with N-SBP, 
p=0.321]. In another 6 (4.6%) patients, paracentesis was re-
peated because they did not show clinical improvement in 
spite of a decrease in ascitic fluid PMN count [4 (3.6%) with 
CA-SBP vs. 2 (10.5%) with N-SBP, p=0.092].
 
Microbiological characteristics of ascitic fluid and blood
The organisms cultured from the ascitic fluid are listed in 
Table 2. Pathogens were isolated in 37 (28.5%) of 130 ascit-
Table 2. Ascitic Fluid Culture Positivity and Isolated Organisms
CA-SBP (n=111) N-SBP (n=19) p value
AF culture positivity 32 (28.8) 5 (26.3) 0.961
Organisms
    Escherichia coli 20 (62.5) 3 (60.0) -
    Aeromonas   4 (12.5) 1 (20.0) -
    Streptococcos 3 (9.4) 1 (20.0) -
    Klebsiella 3 (9.4) - -
    Pseudomonas 2 (6.2) - -
CA-SBP, community acquired spontaneous bacterial peritonitis; N-SBP, nosocomial spontaneous bacterial peritonitis; AF, ascitic fluid.
Variables are expressed as n (%).
Table 1. Baseline Characteristics of Patients with CA-SBP and Patients with N-SBP at the Time of Diagnosis
Total (n=130) CA-SBP (n=111, 85.4%) N-SBP (n=19, 14.6%) p value
Age (yrs)   53.3±8.4   53.8±8.1   50.1±9.4 0.086
Male 88 (67.7) 72 (64.9) 16 (84.2) 0.108
History of previous variceal bleeding 35 (26.9) 31 (27.9) 4 (21.1) 0.534
History of previous hepatic encephalopathy 35 (26.9) 29 (26.1) 6 (31.6) 0.621
Child-Pugh score   10.7±1.9   10.9±1.9     9.9±1.7 0.407
Serum analysis
    WBC count (/mm3)     7985±4864     8197±4978     4780±2244 0.006
    Albumin (g/dL)     2.5±0.5     2.5±0.5     2.6±0.4 0.476
    Total bilirubin (mg/dL)     5.7±4.4     5.6±4.5     6.3±3.7 0.572
    Creatinine (mg/dL)     1.3±1.0     1.3±1.1     1.2±0.4 0.725
    Sodium (mmol/L) 131.8±5.8 131.6±5.8 135.4±5.8 0.007
    Prothrombin time (INR)     2.16±1.15     2.17±1.18     2.10±0.99 0.756
    CRP (mg/L)     4.42±3.78     4.02±3.25     5.57±4.19 0.217
Ascitic fluid analysis
    WBC count (/mm3)     7006±6231     7457±6510     4372±2393 0.861
    PMN count (/mm3)     6390±5611     6327±5886     6756±3615 0.873
    Protein (g/dL)     1.21±0.98     1.22±1.05     1.18±0.50 0.833
    Albumin (g/dL)     0.55±0.32     0.54±0.31     0.58±0.38 0.689
CA-SBP, community acquired spontaneous bacterial peritonitis; N-SBP, nosocomial spontaneous bacterial peritonitis; WBC, white blood cell; CRP, C-reac-
tive protein; PMN, polymorphonuclear leukocytes; INR, international normalized ratio.
Variables are expressed as mean±SD or n (%).
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iate analysis identified ascitic fluid culture positivity as the 
only independent predictor of in-hospital mortality (p=0.036; 
HR, 5.392; 95% CI, 1.208-24.061).
Time to recurrence
In total, 104 (93.7%) patients with CA-SBP and 16 (84.2%) 
with N-SBP survived their first episode of SBP. After dis-
charge, SBP recurred in 42 (40.4%) of 104 patients with 
CA-SBP and 6 (37.5%) of 16 with N-SBP after a median 
period of 4.7 months (range, 0.8-29.5) and 3.6 months 
(range, 1.3-12.8), respectively (p=0.925) (Fig. 1). 
Overall survival and its predictors 
The median survival time of the study population was 6.5 
months (range, 0.1-136.1); 117 (90.0%) patients had died by 
the end of the follow-up period. The median survival time of 
Antibiotics were switched in 11 (8.5%) patients, due to 
cefotaxime resistance, treatment failure, or persistent clini-
cal deterioration. Cefotaxime resistance developed in three 
(8.1%) of 37 patients with positive ascitic fluid culture [2 
(6.3%) with CA-SBP vs. 1 (20.0%) with N-SBP, p=0.233]. 
Cefotaxime was switched to carbapenem in 10 patients and 
to ciprofloxacin in one. Among these 11 patients, nine pa-
tients died during hospitalization, while two recovered.
 
Predictors of in hospital mortality 
Table 4 presents the results of the univariate and multivari-
ate analyses to identify the independent predictors of in-
hospital mortality. The univariate analysis demonstrated that 
variceal bleeding during hospitalization and ascitic fluid 
culture positivity significantly predicted in-hospital mortali-
ty (p=0.035 and p=0.031, respectively). However, multivar-
Table 3. Clinical Course during Hospitalization in Patients with CA-SBP and Patients with N-SBP
Variables CA-SBP (n=111) N-SBP (n=19) p value
Variceal bleeding 6 (5.4) 1 (5.3) 0.980 
Hepatic encephalopathy 8 (7.2)   3 (15.8) 0.203 
Renal failure 5 (4.5) 1 (5.3) 0.146 
Blood culture positivity 28 (25.2)   6 (31.6) 0.578 
Antibiotic switching 7 (6.3)   4 (21.1) 0.066
In hospital mortality 7 (6.3)   3 (15.8) 0.163 
CA-SBP, community acquired spontaneous bacterial peritonitis; N-SBP, nosocomial spontaneous bacterial peritonitis. 
Variables are expressed as n (%).
Table 4. Predictors of In-Hospital Mortality
Variables
Died
(n=10, 7.7%)
Survived
(n=120, 92.3%)
Univariate Multivariate
p value p value HR 95% CI
Age (yrs)   52.2±9.2   53.4±8.6 0.679 - - -
Male 5 (50.0) 83 (69.2) 0.223 - - -
Variceal bleeding 3 (30.0) 4 (3.3) 0.035 0.054 18.297 0.526-19.551
Antibiotic switching 2 (20.0) 9 (7.5) 0.201 - - -
Child-Pugh score   11.7±1.9   10.6±1.8 0.070 - - -
Serum
    WBC (/mm3)     9792±7106     7798±4620 0.403 - - -
    Albumin (g/dL)          2.4±0.30       2.4±0.48 0.907 - - -
    Total bilirubin (mg/dL)     6.82±4.78     5.19±4.39 0.116 - - -
    Sodium (mmol/L) 131.8±5.9 132.0±5.8 0.596 - - -
    Prothrombin time (INR)     2.54±1.06     2.10±2.16 0.138 - - -
    CRP (mg/L)     4.98±4.57     4.26±4.33 0.216 - - -
    Culture positivity 1 (10.0) 6 (5.0) 0.132 - - -
Ascitic fluid
    WBC (/mm3)     8125±4253     7786±4630 0.406 - - -
    PMN (/mm3)     7070±4642     5284±5709 0.686 - - -
    Albumin (g/dL)     2.5±0.7     2.4±0.6 0.853 - - -
    Culture positivity 6 (60.0) 31 (25.8) 0.031 0.036 5.392 1.208-24.061
N-SBP 3 (30.0) 16 (13.3) 0.166 - - -
HR, hazard ratio; CI, confidence interval; WBC, white blood cell; CRP, C-reactive protein; PMN, polymorphonuclear leukocytes; N-SBP, nosocomial sponta-
neous bacterial peritonitis; INR, international normalized ratio.
Variables are expressed as mean±SD or n (%). 
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course during hospitalization, time to recurrence and over-
all survival, as well as causes of mortality. These results sug-
gest that these two types of SBP are not different disease 
entities and, furthermore, that the acquisition site of the 
pathogen (community-acquired vs. nosocomial) does not 
affect the prognosis of SBP patients.
To date, few studies have compared the characteristics of 
CA-SBP and N-SBP. Bert, et al.13 found that nosocomial 
isolates were significantly more resistant to amoxicillin/cla-
vulanic acid and cefotaxime than community-acquired iso-
lates and, thus, insisted that N-SBP requires a wider spec-
trum of antibiotics than CA-SBP. Moreover, Cheong, et 
al.11 concluded that nosocomial acquisition of SBP patho-
gens adversely affected the clinical outcomes of SBP, and 
that N-SBP mortality was accordingly higher. In contrast, 
Song, et al.12 reported that acquisition sites of infection did 
not have prognostic significance in SBP, and Umgelter, et 
al.17 concluded that the microbiological patterns and out-
comes of CA-SBP and N-SBP did not differ. Therefore, dif-
ferences in the prognosis of CA-SBP and N-SBP still re-
main unresolved. We believe that the discrepancies among 
these previous studies are a result of heterogeneity in their 
study populations caused by differences in baseline liver 
functions between patients with CA-SBP and N-SBP, the 
inclusion of patients with a history of previous SBP, coex-
isting HCC in some patients at baseline, and various etiolo-
gies of liver cirrhosis.11-13
Our study differs from previous studies in several ways. 
First, the baseline characteristics, including liver function, 
patients with CA-SBP was 6.6 months (range, 0.1-128.1), 
and that of patients with N-SBP was 6.2 months (range, 0.2-
136.1) (p=0.569) (Fig. 2). The 1-, 6-, and 12-month cumula-
tive mortality rates of patients with CA-SBP were 7.2%, 
48.7% and 64.2%, respectively, and those for patients with 
N-SBP were 15.8%, 47.6%, and 70.9%, respectively. The 
Cox-regression hazard model revealed that Child-Pugh 
score (p=0.001; HR, 1.312; 95% CI, 1.122-1.536) and serum 
sodium level (p=0.007; HR, 0.946; 95% CI, 0.909-0.985) 
were independent predictors of overall survival (Table 5). 
Causes of mortality 
Causes of in-hospital and overall mortality are summarized 
in Table 6. Septic shock was the most common cause of in-
hospital mortality [three (42.9%) with CA-SBP and one 
(33.3%) with N-SBP, p=0.087]. Concerning overall mortal-
ity, gastrointestinal bleeding (21.5%), hepatic failure (21.5%) 
and septic shock (20.4%) were common in patients with 
CA-SBP, whereas gastrointestinal bleeding (21.4%), septic 
shock (21.4%), renal failure (21.4%), and HE (21.4%) were 
common in those with N-SBP. Causes of in-hospital and 
overall mortality did not significantly differ between the 
two groups (p=0.917 and 0.375, respectively).
DISCUSSION
Patients with CA-SBP and N-SBP in this study showed 
similar clinical and microbiological characteristics, clinical 
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Fig. 1. Cumulative recurrence-free curves of patients with CA-SBP and pa-
tients with N-SBP. Time to recurrence was not different between the 
groups [median 4.7 months (range, 0.8-29.5) vs. 3.6 months (range, 1.3-12.8), 
p=0.925]. CA-SBP, community acquired spontaneous bacterial peritonitis; 
N-SBP, nosocomial spontaneous bacterial peritonitis; 
Fig. 2. Cumulative overall survival curves of patients with CA-SBP and pa-
tients with N-SBP. Overall survival was not different between the groups 
[median 6.6 months (range, 0.1-128.1) vs. 6.2 months (range, 0.2-136.1), p= 
0.569]. CA-SBP, community acquired spontaneous bacterial peritonitis; 
N-SBP, nosocomial spontaneous bacterial peritonitis; 
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preserved, indicating that CA-SBP and N-SBP may be of 
the same spectrum of SBP and that vulnerability to SBP is 
determined only by liver function status throughout the 
course of liver disease. This idea is also supported by the 
fact that SBP is a problem of increased gut permeability and 
bacterial translocation resulting from the intrinsic patho-
physiological process of each individual patient and is not 
caused by pathogens from outside of the body.24 
Second, our study included only patients who had experi-
enced their first episode of SBP. The chance of exposure to 
more resistant pathogen strains increases as patients experi-
ence repeated SBP events and admissions.17 Therefore, it is 
difficult to purely compare the effect of acquisition site of 
were similar between enrolled patients with CA-SBP and 
N-SBP. Therefore, we could exclude the potential confound-
ing effects of different liver function on the prognosis of 
CA-SBP and N-SBP. Although a previous study revealed 
that patients with N-SBP showed poorer prognosis and 
were infected by more virulent organisms than those with 
CA-SBP,11 baseline liver function was more favorable in 
patients with CA-SBP. Thus, the poor prognosis for patients 
with N-SBP might have been caused by poorer baseline liv-
er function alone, and not by any inherent characteristics of 
N-SBP. According to our results, discrimination between 
CA-SBP and N-SBP may be meaningless, at least for the 
first episode of SBP, when liver function is relatively well 
Table 5. Predictors of Overall Survival
Variables
Univariate Multivariate
p value p value HR 95% CI
Age (yrs) 0.059 - - -
Male 0.193 - - -
Variceal bleeding 0.210 - - -
Child-Pugh score <0.001 0.001 1.312 1.122-1.536
Serum
    WBC (/mm3) 0.957 - - -
    Albumin (g/dL) 0.084 - - -
    Total bilirubin (mg/dL) 0.019 0.567 1.987 0.942-1.033
    Sodium (mmol/L) 0.002 0.007 0.946 0.909-0.985
    Prothrombin time (INR) 0.001 0.805 1.965 0.726-1.282
    CRP (mg/L) 0.265
    Culture positivity 0.120 -
Ascitic fluid
    WBC (/mm3) 0.649 - - -
    PMN (/mm3) 0.736 - - -
    Albumin (g/dL) 0.237 - - -
    Culture positivity 0.419 - - -
N-SBP 0.570 - - -
HR, hazard ratio; CI, confidence interval; WBC, white blood cell; CRP, C-reactive protein;  PMN, polymorphonuclear leukocytes; N-SBP, nosocomial sponta-
neous bacterial peritonitis; INR, international normalized ratio.
Variables are expressed as mean±SD or n (%). 
Table 6. Causes of Mortality
In hospital mortality Overall mortality
CA-SBP (n=7) N-SBP (n=3) CA-SBP (n=93) N-SBP (n=14)
Septic shock   3 (42.9)   1 (33.3) 19 (20.4)   3 (21.4)
Gastrointestinal bleeding   1 (14.3) 0 (0.0) 20 (21.5)   3 (21.4)
Hepatic failure 0 (0.0)   1 (33.3) 20 (21.5) 1 (7.2)
Hepatocellular carcinoma 0 (0.0) 0 (0.0) 4 (4.3) 1 (7.2)
Renal failure 0 (0.0)   1 (33.3) 5 (5.4)   3 (21.4)
Hepatic encephalopathy   2 (28.5) 0 (0.0) 13 (14.0)   3 (21.4)
Other   1 (14.3) 0 (0.0) 3 (3.2) 0 (0.0)
Unknown 0 (0.0) 0 (0.0) 9 (9.7) 0 (0.0)
CA-SBP, community acquired spontaneous bacterial peritonitis; N-SBP, nosocomial spontaneous bacterial peritonitis.
Variables are expressed as n (%).
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terial infection, and that the third-generation cephalosporin 
cefotaxime is sufficient as a first-line treatment in patients 
experiencing their first episode of SBP, regardless of the ac-
quisition site of infection. 
The acquisition site of SBP pathogen did not affect the 
clinical course during hospitalization or in-hospital mortali-
ty in our study. Ascitic fluid culture positivity was the only 
significant predictor of in-hospital mortality.20 Furthermore, 
only Child-Pugh scores and serum sodium levels signifi-
cantly predicted overall survival, while the acquisition site 
of the infection did not. Moreover, we found no statistical 
differences between patients with CA-SBP and N-SBP re-
garding overall survival, time to recurrence, and causes of 
mortality. All these results suggest that these two types of 
SBP are similar disease entities.
Despite the unique features of the present study, there are 
some limitations. First, because this study was retrospective-
ly designed, the sample size is relatively small, particularly 
the group of patients with N-SBP. Moreover, follow-up 
paracentesis, 48 hours after antibiotics administration, was 
performed in only 58.5% of patients (60.4% with CA-SBP 
and 47.4% with N-SBP). Lastly, the microbiology of SBP 
may have changed over the long study period from 1999 to 
2008. We were not able to stratify the organisms of SBP ac-
cording to the time period because the number of isolated 
organisms was too small. Therefore, future prospectively 
designed studies incorporating a larger number of patients 
should be performed to overcome these limitations. 
In conclusion, the acquisition site of infection (communi-
ty-acquired vs. nosocomial) did not affect the clinical out-
comes and prognosis of patients with HBV-related liver cir-
rhosis who had experienced their first episode of SBP. Third-
generation cephalosporins may be effective in empirically 
treating these patients, regardless of the acquisition site of 
infection.
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